Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.95 – $6.10
94% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $19.8K | $38.2K | $39.6K | $42.6K | $115.1K | $145.0K | $58.2K |
| Gross profit | $0 | −$19.8K | −$38.2K | −$39.6K | −$42.6K | −$115.1K | −$145.0K | −$58.2K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $0 | $780.4K | $6.4M | $6.2M | $6.9M | $16.6M | $8.0M | $15.7M |
| Operating income | −$11.8K | −$1.4M | −$9.9M | −$11.2M | −$12.9M | −$22.8M | −$17.8M | −$24.9M |
| EBITDA | $0 | −$1.3M | −$9.8M | −$11.2M | −$12.8M | −$22.7M | −$17.7M | −$24.9M |
| Net income | −$11.8K | −$1.4M | −$9.8M | −$11.2M | −$12.7M | −$20.7M | −$22.4M | −$24.0M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.00 | -0.05 | -0.38 | -0.35 | -0.32 | -0.39 | -0.38 | -0.36 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-0.30 | $-0.30–$-0.30 | 1 |
| 2027 | $0 | $-0.26 | $-0.26–$-0.26 | 1 |
| 2028 | $0 | $0.01 | $0.01–$0.01 | 1 |
| 2029 | $0 | $2.10 | $2.10–$2.10 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds NGENF.
No tracked institution reports a position in NGENF as of their last filing.
No one on the platform has traded NGENF yet.
| $539M |
| — |
| IPHYFInnate Pharma S.A. | $1.65 | +0.00% | $155M | — |
| JWCTFJW (Cayman) Therapeutics Co. Ltd | $0.24 | +0.00% | $99M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.